<p>儘管已經有了強勁的表現，<strong>Arcutis Biotherapeutics, Inc.</strong>（納斯達克代碼：ARQT）股票仍在繼續上漲，過去三十天上漲了 28%。在最新的上漲之後，年增幅達到了 147%，引起了投資者的關注。</p>
<p>儘管價格有了明顯的反彈，但你仍然可以理解對 Arcutis Biotherapeutics 的市銷率為 12 倍感到無動於衷，因為美國生物科技行業的中位市銷率也接近 12.1 倍。雖然這可能不會引起任何人的注意，但如果市銷率沒有合理的依據，投資者可能會錯過潛在的機會或忽視即將到來的失望。</p>
<p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</p>
<p>查看我們對 Arcutis Biotherapeutics 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/549019944-ps-multiple-vs-industry-1-dark-2/1765282375082?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/549019944-ps-multiple-vs-industry-1-dark-2/1765282375082"/></p>
<p>納斯達克 GS:ARQT 市銷率與行業比較 2025 年 12 月 9 日</p>
<h3>Arcutis Biotherapeutics 最近的表現如何？</h3>
<p>最近一段時間，Arcutis Biotherapeutics 的表現並不理想，因為其收入增長速度低於大多數其他公司。一個可能的原因是，市銷率適中，因為投資者認為這種乏力的收入表現會有所好轉。如果沒有，那麼現有股東可能會對股價的可持續性感到有些緊張。</p>
<p>如果你想了解分析師對未來的預測，可以查看我們對 Arcutis Biotherapeutics 的 <strong>免費</strong> 報告。</p>
<h2>Arcutis Biotherapeutics 是否有收入增長的預測？</h2>
<p>Arcutis Biotherapeutics 的市銷率對於一家預計僅能實現適度增長的公司來説是典型的，重要的是，它的表現與行業保持一致。</p>
<p>回顧過去一年，公司營收實現了 129% 的驚人增長。最近三年期間，收入也經歷了令人難以置信的整體增長，這得益於其出色的短期表現。因此，我們可以首先確認公司在這段時間內在收入增長方面做得非常出色。</p>
<p>展望未來，覆蓋該公司的八位分析師的估計顯示，未來三年收入預計將以每年 32% 的速度增長。這一增速明顯低於更廣泛行業的 130% 的年增長預測。</p>
<p>根據這些信息，我們發現 Arcutis Biotherapeutics 的市銷率與行業相對接近，這很有趣。似乎大多數投資者忽視了相對有限的增長預期，並願意為接觸該股票支付更高的價格。如果市銷率降至與增長前景更為一致的水平，這些股東可能會為未來的失望埋下伏筆。</p>
<h2>Arcutis Biotherapeutics 的市銷率對投資者意味着什麼？</h2>
<p>Arcutis Biotherapeutics 似乎重新受到青睞，價格大幅上漲使其市銷率迴歸到行業其他公司的水平。然而，僅僅依靠市銷率來判斷是否應該出售你的股票並不明智，但它可以作為公司未來前景的實用指南。</p>
<p>鑑於 Arcutis Biotherapeutics 的收入增長預測相對温和，與更廣泛的行業相比，看到其以當前市銷率交易令人感到驚訝。目前，我們對市銷率並不樂觀，因為預測的未來收入不太可能長期支持更積極的市場情緒。這樣的情況對當前和潛在投資者構成風險，如果低收入增長影響市場情緒，股價可能會下跌。</p>
<p>我們不想過於潑冷水，但我們確實發現了 <strong>1 個需要注意的警告信號</strong>，關於 Arcutis Biotherapeutics。</p>
<p>如果這些 <strong>風險讓你重新考慮對 Arcutis Biotherapeutics 的看法</strong>，請查看我們的高質量股票互動列表，以瞭解還有哪些其他選擇。</p>

ARQT

<p>Arcutis Biotherapeutics, Inc.（納斯達克代碼：ARQT）股票在過去 30 天內上漲了 28%，使其年增幅達到 147%。儘管價格上漲，其市銷率為 12 倍，與生物科技行業平均水平相符。分析師預測未來三年的年收入增長率為 32%，低於行業的 130%。如果增長預期未能實現，投資者可能會感到失望，因為當前的市銷率可能無法持續</p>

<p>Despite an already strong run, <strong>Arcutis Biotherapeutics, Inc.</strong> (NASDAQ:ARQT) shares have been powering on, with a gain of 28% in the last thirty days. The annual gain comes to 147% following the latest surge, making investors sit up and take notice.</p>
<div class="lb-trans"><p>儘管已經有了強勁的表現，<strong>Arcutis Biotherapeutics, Inc.</strong>（納斯達克代碼：ARQT）股票仍在繼續上漲，過去三十天上漲了 28%。在最新的上漲之後，年增幅達到了 147%，引起了投資者的關注。</p>
</div><p>In spite of the firm bounce in price, you could still be forgiven for feeling indifferent about Arcutis Biotherapeutics' P/S ratio of 12x, since the median price-to-sales (or &#34;P/S&#34;) ratio for the Biotechs industry in the United States is also close to 12.1x. While this might not raise any eyebrows, if the P/S ratio is not justified investors could be missing out on a potential opportunity or ignoring looming disappointment.</p>
<div class="lb-trans"><p>儘管價格有了明顯的反彈，但你仍然可以理解對 Arcutis Biotherapeutics 的市銷率為 12 倍感到無動於衷，因為美國生物科技行業的中位市銷率也接近 12.1 倍。雖然這可能不會引起任何人的注意，但如果市銷率沒有合理的依據，投資者可能會錯過潛在的機會或忽視即將到來的失望。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</p>
</div><p>Check out our latest analysis for Arcutis Biotherapeutics</p>
<div class="lb-trans"><p>查看我們對 Arcutis Biotherapeutics 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/549019944-ps-multiple-vs-industry-1-dark-2/1765282375082" alt="" original-src="https://images.simplywall.st/asset/chart/549019944-ps-multiple-vs-industry-1-dark-2/1765282375082"/></p>
<p>NasdaqGS:ARQT Price to Sales Ratio vs Industry December 9th 2025</p>
<div class="lb-trans"><p>納斯達克 GS:ARQT 市銷率與行業比較 2025 年 12 月 9 日</p>
</div><h3>How Has Arcutis Biotherapeutics Performed Recently?</h3>
<div class="lb-trans"><h3>Arcutis Biotherapeutics 最近的表現如何？</h3>
</div><p>Recent times haven't been great for Arcutis Biotherapeutics as its revenue has been rising slower than most other companies. One possibility is that the P/S ratio is moderate because investors think this lacklustre revenue performance will turn around. If not, then existing shareholders may be a little nervous about the viability of the share price.</p>
<div class="lb-trans"><p>最近一段時間，Arcutis Biotherapeutics 的表現並不理想，因為其收入增長速度低於大多數其他公司。一個可能的原因是，市銷率適中，因為投資者認為這種乏力的收入表現會有所好轉。如果沒有，那麼現有股東可能會對股價的可持續性感到有些緊張。</p>
</div><p>If you'd like to see what analysts are forecasting going forward, you should check out our <strong>free</strong> report on Arcutis Biotherapeutics.</p>
<div class="lb-trans"><p>如果你想了解分析師對未來的預測，可以查看我們對 Arcutis Biotherapeutics 的 <strong>免費</strong> 報告。</p>
</div><h2>Is There Some Revenue Growth Forecasted For Arcutis Biotherapeutics?</h2>
<div class="lb-trans"><h2>Arcutis Biotherapeutics 是否有收入增長的預測？</h2>
</div><p>Arcutis Biotherapeutics' P/S ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the industry.</p>
<div class="lb-trans"><p>Arcutis Biotherapeutics 的市銷率對於一家預計僅能實現適度增長的公司來説是典型的，重要的是，它的表現與行業保持一致。</p>
</div><p>Retrospectively, the last year delivered an exceptional 129% gain to the company's top line. The latest three year period has also seen an incredible overall rise in revenue, aided by its incredible short-term performance. So we can start by confirming that the company has done a tremendous job of growing revenue over that time.</p>
<div class="lb-trans"><p>回顧過去一年，公司營收實現了 129% 的驚人增長。最近三年期間，收入也經歷了令人難以置信的整體增長，這得益於其出色的短期表現。因此，我們可以首先確認公司在這段時間內在收入增長方面做得非常出色。</p>
</div><p>Shifting to the future, estimates from the eight analysts covering the company suggest revenue should grow by 32% per annum over the next three years. That's shaping up to be materially lower than the 130% per year growth forecast for the broader industry.</p>
<div class="lb-trans"><p>展望未來，覆蓋該公司的八位分析師的估計顯示，未來三年收入預計將以每年 32% 的速度增長。這一增速明顯低於更廣泛行業的 130% 的年增長預測。</p>
</div><p>With this information, we find it interesting that Arcutis Biotherapeutics is trading at a fairly similar P/S compared to the industry. It seems most investors are ignoring the fairly limited growth expectations and are willing to pay up for exposure to the stock. These shareholders may be setting themselves up for future disappointment if the P/S falls to levels more in line with the growth outlook.</p>
<div class="lb-trans"><p>根據這些信息，我們發現 Arcutis Biotherapeutics 的市銷率與行業相對接近，這很有趣。似乎大多數投資者忽視了相對有限的增長預期，並願意為接觸該股票支付更高的價格。如果市銷率降至與增長前景更為一致的水平，這些股東可能會為未來的失望埋下伏筆。</p>
</div><h2>What Does Arcutis Biotherapeutics' P/S Mean For Investors?</h2>
<div class="lb-trans"><h2>Arcutis Biotherapeutics 的市銷率對投資者意味着什麼？</h2>
</div><p>Arcutis Biotherapeutics appears to be back in favour with a solid price jump bringing its P/S back in line with other companies in the industry Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.</p>
<div class="lb-trans"><p>Arcutis Biotherapeutics 似乎重新受到青睞，價格大幅上漲使其市銷率迴歸到行業其他公司的水平。然而，僅僅依靠市銷率來判斷是否應該出售你的股票並不明智，但它可以作為公司未來前景的實用指南。</p>
</div><p>Given that Arcutis Biotherapeutics' revenue growth projections are relatively subdued in comparison to the wider industry, it comes as a surprise to see it trading at its current P/S ratio. At present, we aren't confident in the P/S as the predicted future revenues aren't likely to support a more positive sentiment for long. Circumstances like this present a risk to current and prospective investors who may see share prices fall if the low revenue growth impacts the sentiment.</p>
<div class="lb-trans"><p>鑑於 Arcutis Biotherapeutics 的收入增長預測相對温和，與更廣泛的行業相比，看到其以當前市銷率交易令人感到驚訝。目前，我們對市銷率並不樂觀，因為預測的未來收入不太可能長期支持更積極的市場情緒。這樣的情況對當前和潛在投資者構成風險，如果低收入增長影響市場情緒，股價可能會下跌。</p>
</div><p>We don't want to rain on the parade too much, but we did also find <strong>1 warning sign for Arcutis Biotherapeutics</strong> that you need to be mindful of.</p>
<div class="lb-trans"><p>我們不想過於潑冷水，但我們確實發現了 <strong>1 個需要注意的警告信號</strong>，關於 Arcutis Biotherapeutics。</p>
</div><p>If these <strong>risks are making you reconsider your opinion on Arcutis Biotherapeutics</strong>, explore our interactive list of high quality stocks to get an idea of what else is out there.</p>
<div class="lb-trans"><p>如果這些 <strong>風險讓你重新考慮對 Arcutis Biotherapeutics 的看法</strong>，請查看我們的高質量股票互動列表，以瞭解還有哪些其他選擇。</p>
</div>

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) 的股票上漲了 28%，因為投資者的悲觀情緒比預期要低